INSPIRE

• Research type

  Research Study

• Full title

  INjectable treatments for patients with Shoulder Pain: a prospective observatIonal study to deteRmine Efficacy: Does injection treatment improve 26-week shoulder symptoms? A multi-centre, observational, prospective study

• IRAS ID

  302987

• Contact name

  Gui Tran

• Contact email

  gui.tran@nhs.net

• Sponsor organisation

  Harrogate and District NHS Foundation Trust

• Duration of Study in the UK

  3 years, 1 months, 0 days

• Research summary

  Shoulder pain is common and persistent, and increases with age. Current treatment includes glenohumeral joint (GHJ) steroid injections and suprascapular nerve blocks (SSNB), but robust evidence is lacking. Further work is required to evaluate the effectiveness of these injectable therapies which are already undertaken in the normal NHS pathway.

  We are proposing an observational cohort study in patients with shoulder pain. Patients who have shoulder pain and receive SSNB or GHJ steroid injections as part of their routine NHS care will be asked if they would like to take part in this study. Patients who do not receive these treatments will also be asked to take part. If patients consent, they will be asked to complete a 5-10 minute questionnaire at baseline, week 2, 12 and 26. The answer to these questionnaires will allow us to understand the effectiveness of these treatments.

  Inclusion criteria:

  • Age > 18
  • Ability to provide informed consent
  • Imaging-detected GHJ OA or RC arthropathy
  • Shoulder pain (if bilateral shoulder pain with GHJ OA, the shoulder receiving the therapy will be the target shoulder)

  Exclusion criteria:
  • The presence of any inflammatory arthritis (including gout, reactive arthritis, rheumatoid arthritis, psoriatic arthritis, seronegative spondylarthropathy)
  • Use of IA, IM, oral steroids 12 weeks prior to preceding enrolment
  • History of ipsilateral shoulder joint replacement
  • Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease
  • Diagnosed with fibromyalgia or complex regional pain syndrome
  • Adhesive Capsulitis

  The study will be undertaken at both Primary and Secondary care. It is expected that participants will be recruited and all data collected within 2 years.
  The results of this study will enable a better understanding of its role in the healthcare pathway and underpin a randomised control trial.
  

• REC name

  HSC REC B

• REC reference

  21/NI/0181

• Date of REC Opinion

  11 Nov 2021

• REC opinion

  Further Information Favourable Opinion